Atopic Dermatitis (AD) Clinical Trial
Official title:
Skin Barrier in Childhood Atopic Dermatitis With and Without Food Allergy (ADRN-10)
This is a prospective, single center, clinical mechanistic pilot clinical research study. Participants will not receive any investigational agent. The investigators will examine whether children with atopic dermatitis (AD) and food allergy have a different skin barrier, microbiome, epidermal transcriptome, and epidermal lipid composition than children with AD and no food allergy and non-atopic (NA) children. Participation involves a single study visit.
Atopic Dermatitis (AD) is a chronic inflammatory skin disorder in which the skin becomes
extremely itchy and is susceptible to recurrent skin infections. AD is thought to occur from
a combination of immunological, genetic, and environmental factors.
Those with atopic dermatitis (AD) often have food allergy and Staphylococcus aureus (S.
aureus) colonization of the skin. There is evidence suggesting that skin barrier dysfunction,
measurable as increased transepidermal water loss (TEWL), is a predisposing factor to food
sensitization and food allergy from epicutaneous penetration of environmental food allergens.
Furthermore, the investigators for this study have identified that AD children with food
allergy, especially peanut allergy, are colonized with Staphylococcus aureus. However, only
half (50%) of children with AD have food allergy or S. aureus colonization, suggesting there
are other factors accounting for food allergy. There have been no previous studies of TEWL
or, microbial or molecular profiling of the skin in those with AD prone to food allergy
versus AD without food allergy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03151148 -
Targeted Microbiome Transplant in Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05456529 -
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT04056130 -
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04173442 -
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
|
||
| Completed |
NCT05372653 -
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
|
Phase 3 | |
| Terminated |
NCT03389893 -
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT04541810 -
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
|
||
| Completed |
NCT02357940 -
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
|
N/A | |
| Recruiting |
NCT05667623 -
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
|
Phase 3 | |
| Recruiting |
NCT05650320 -
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD
|
Phase 3 | |
| Completed |
NCT01979016 -
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
|
Phase 2 | |
| Withdrawn |
NCT04666675 -
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
|
Phase 3 | |
| Active, not recruiting |
NCT05959083 -
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
|
||
| No longer available |
NCT04159597 -
Expanded Access to Upadacitinib
|